Background Treatment for patent ductus arteriosus (PDA) in premature infants may fail following perinatal indomethacin exposure. Glibenclamide, a sulfonylurea, constricts the fetal rabbit ductus in vitro , and fetal rat ductus in vivo . Clinical doses for diabetes include 0.1 mg/kg (adults) and 1 mg/kg (children with neonatal diabetes).
Aims To show ductus constriction acceleration with Glibenclamide in newborn rats as a model of treatment for premature PDA.
Methods Glibenclamide (1 mg/Kg) was injected intraperitoneally (IP) to newborn Wistar rats immediately after cesarian section, and the ductus diameter was studied at 60 min with rapid whole-body freezing, by cutting on a freezing microtome, and measurements performed on a microscope using a micrometre. Two near-term rat models were studied on the 21st day. In a chronic fetal indomethacin-exposure model, mother rats were treated with indomethacin (10 mg/kg, gavage) for two days before birth. In a hypoxia model, neonates were incubated in 8% oxygen. In a premature model, rats were delivered on the 19th day (two days before term) and incubated in 80% oxygen.
Results In these three models, neonatal ductus constricted slowly. Glibenclamide 1 mg/kg, caused accelerated constriction and the effects were dose-dependent. Glibenclamide (1mg/kg, IP) was associated with hypoglycemia, which was controlled with 50% glucose via gavage.
Conclusions Glibenclamide (1 mg/kg, IP) constricts the neonatal ductus in 60 min in three rat models. Hypoglycemia was controlled with glucose, indicating its usefulness in the treatment of PDA in premature infants.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.